This HTML5 document contains 173 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/chebi/
n10http://linked.opendata.cz/resource/AHFS/
n23http://linked.opendata.cz/resource/drugbank/company/
n27http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/kegg-compound/
n33http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/pubchem-substance/
n24http://linked.opendata.cz/resource/drugbank/patent/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/drugbank/
n31http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/iuphar/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/guide-to-pharmacology/
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
n26http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/national-drug-code-directory/
n6http://www.drugs.com/cdi/
n28http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n32http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB01224/identifier/chemspider/
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01224
rdf:type
n3:Drug
n3:description
Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.
n3:dosage
n22:271B59E1-363D-11E5-9242-09173F13E4C5 n22:271B59E2-363D-11E5-9242-09173F13E4C5 n22:271B59E3-363D-11E5-9242-09173F13E4C5 n22:271B59E4-363D-11E5-9242-09173F13E4C5 n22:271B59E5-363D-11E5-9242-09173F13E4C5 n22:271B59E6-363D-11E5-9242-09173F13E4C5 n22:271B59E7-363D-11E5-9242-09173F13E4C5 n22:271B59E8-363D-11E5-9242-09173F13E4C5 n22:271B59DA-363D-11E5-9242-09173F13E4C5 n22:271B59DB-363D-11E5-9242-09173F13E4C5 n22:271B59DC-363D-11E5-9242-09173F13E4C5 n22:271B59DD-363D-11E5-9242-09173F13E4C5 n22:271B59DE-363D-11E5-9242-09173F13E4C5 n22:271B59DF-363D-11E5-9242-09173F13E4C5 n22:271B59E0-363D-11E5-9242-09173F13E4C5 n22:271B59E9-363D-11E5-9242-09173F13E4C5 n22:271B59EA-363D-11E5-9242-09173F13E4C5 n22:271B59EB-363D-11E5-9242-09173F13E4C5 n22:271B59EC-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Dev V, Raniwalla J: Quetiapine: a review of its safety in the management of schizophrenia. Drug Saf. 2000 Oct;23(4):295-307. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11051217 # Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2003 Fall;13(3):295-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14642017 # Tallerico T, Novak G, Liu IS, Ulpian C, Seeman P: Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Res Mol Brain Res. 2001 Mar 5;87(2):160-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11245917 # Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18537577
n3:group
approved
n3:halfLife
6 hours
n3:indication
For the treatment of schizophrenia and related psychotic disorders.
owl:sameAs
n31:DB01224 n33:DB01224
dcterms:title
Quetiapine
adms:identifier
n12:46504800 n13:PA451201 n14:5002 n15:C07397 n16:0310-0275-10 n17:50 n18:50 n19:DB01224 n20:8707 n21:4827 n25:Quetiapine
n3:mechanismOfAction
Quetiapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
n3:packager
n23:271B598B-363D-11E5-9242-09173F13E4C5 n23:271B598C-363D-11E5-9242-09173F13E4C5 n23:271B598F-363D-11E5-9242-09173F13E4C5 n23:271B5990-363D-11E5-9242-09173F13E4C5 n23:271B598D-363D-11E5-9242-09173F13E4C5 n23:271B598E-363D-11E5-9242-09173F13E4C5 n23:271B5993-363D-11E5-9242-09173F13E4C5 n23:271B5994-363D-11E5-9242-09173F13E4C5 n23:271B5991-363D-11E5-9242-09173F13E4C5 n23:271B5992-363D-11E5-9242-09173F13E4C5 n23:271B5997-363D-11E5-9242-09173F13E4C5 n23:271B5998-363D-11E5-9242-09173F13E4C5 n23:271B5995-363D-11E5-9242-09173F13E4C5 n23:271B5996-363D-11E5-9242-09173F13E4C5 n23:271B599B-363D-11E5-9242-09173F13E4C5 n23:271B599C-363D-11E5-9242-09173F13E4C5 n23:271B5999-363D-11E5-9242-09173F13E4C5 n23:271B599A-363D-11E5-9242-09173F13E4C5 n23:271B599F-363D-11E5-9242-09173F13E4C5 n23:271B59A0-363D-11E5-9242-09173F13E4C5 n23:271B599D-363D-11E5-9242-09173F13E4C5 n23:271B599E-363D-11E5-9242-09173F13E4C5 n23:271B59A3-363D-11E5-9242-09173F13E4C5 n23:271B59A4-363D-11E5-9242-09173F13E4C5 n23:271B59A1-363D-11E5-9242-09173F13E4C5 n23:271B59A2-363D-11E5-9242-09173F13E4C5 n23:271B59A5-363D-11E5-9242-09173F13E4C5 n23:271B59A6-363D-11E5-9242-09173F13E4C5
n3:patent
n24:2251944 n24:5948437 n24:4879288
n3:routeOfElimination
Elimination of quetiapine is mainly via hepatic metabolism. Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized. Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.
n3:synonym
Quetiapine fumarate Quetiapine hemifumarate Quetiapina Quetiapine 2-[2-(4-Dibenzo[b,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol Quetiapinum
n3:toxicity
Symptoms of overdose include drowsiness and sedation, tachycardia, and hypotension.
n3:volumeOfDistribution
* 10±4 L/kg
n7:hasAHFSCode
n10:28-16-08-04
n3:foodInteraction
Avoid alcohol. Take without regard to meals.
n3:proteinBinding
83%
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Quetiapine.htm
n26:hasConcept
n27:M0189762
foaf:page
n6:quetiapine.html n28:quetiap.htm n32:ser1402.shtml
n3:IUPAC-Name
n4:271B59F1-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B59F7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B59F6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B59F3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B59F4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B59F5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5A07-363D-11E5-9242-09173F13E4C5 n4:271B59EF-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B59F0-363D-11E5-9242-09173F13E4C5 n4:271B5A08-363D-11E5-9242-09173F13E4C5 n4:271B59ED-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B59EE-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:N05AH04
n3:H-Bond-Acceptor-Count
n4:271B59FD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B59FE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B59F8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B59F9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B59FB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B59FA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B59FC-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly and well absorbed.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
111974-69-7
n3:category
n3:containedIn
n9:271B59B2-363D-11E5-9242-09173F13E4C5 n9:271B59B3-363D-11E5-9242-09173F13E4C5 n9:271B59B1-363D-11E5-9242-09173F13E4C5 n9:271B59B6-363D-11E5-9242-09173F13E4C5 n9:271B59B7-363D-11E5-9242-09173F13E4C5 n9:271B59B4-363D-11E5-9242-09173F13E4C5 n9:271B59B5-363D-11E5-9242-09173F13E4C5 n9:271B59B8-363D-11E5-9242-09173F13E4C5 n9:271B59BA-363D-11E5-9242-09173F13E4C5 n9:271B59BB-363D-11E5-9242-09173F13E4C5 n9:271B59B9-363D-11E5-9242-09173F13E4C5 n9:271B59BE-363D-11E5-9242-09173F13E4C5 n9:271B59BF-363D-11E5-9242-09173F13E4C5 n9:271B59BC-363D-11E5-9242-09173F13E4C5 n9:271B59BD-363D-11E5-9242-09173F13E4C5 n9:271B59C2-363D-11E5-9242-09173F13E4C5 n9:271B59C3-363D-11E5-9242-09173F13E4C5 n9:271B59C0-363D-11E5-9242-09173F13E4C5 n9:271B59C1-363D-11E5-9242-09173F13E4C5 n9:271B59C6-363D-11E5-9242-09173F13E4C5 n9:271B59C7-363D-11E5-9242-09173F13E4C5 n9:271B59C4-363D-11E5-9242-09173F13E4C5 n9:271B59C5-363D-11E5-9242-09173F13E4C5 n9:271B59CA-363D-11E5-9242-09173F13E4C5 n9:271B59CB-363D-11E5-9242-09173F13E4C5 n9:271B59C8-363D-11E5-9242-09173F13E4C5 n9:271B59C9-363D-11E5-9242-09173F13E4C5 n9:271B59CE-363D-11E5-9242-09173F13E4C5 n9:271B59CF-363D-11E5-9242-09173F13E4C5 n9:271B59CC-363D-11E5-9242-09173F13E4C5 n9:271B59CD-363D-11E5-9242-09173F13E4C5 n9:271B59D2-363D-11E5-9242-09173F13E4C5 n9:271B59D3-363D-11E5-9242-09173F13E4C5 n9:271B59D0-363D-11E5-9242-09173F13E4C5 n9:271B59D1-363D-11E5-9242-09173F13E4C5 n9:271B59D6-363D-11E5-9242-09173F13E4C5 n9:271B59D7-363D-11E5-9242-09173F13E4C5 n9:271B59D4-363D-11E5-9242-09173F13E4C5 n9:271B59D5-363D-11E5-9242-09173F13E4C5 n9:271B59D8-363D-11E5-9242-09173F13E4C5 n9:271B59D9-363D-11E5-9242-09173F13E4C5 n9:271B59A7-363D-11E5-9242-09173F13E4C5 n9:271B59A8-363D-11E5-9242-09173F13E4C5 n9:271B59AB-363D-11E5-9242-09173F13E4C5 n9:271B59AC-363D-11E5-9242-09173F13E4C5 n9:271B59A9-363D-11E5-9242-09173F13E4C5 n9:271B59AA-363D-11E5-9242-09173F13E4C5 n9:271B59AF-363D-11E5-9242-09173F13E4C5 n9:271B59B0-363D-11E5-9242-09173F13E4C5 n9:271B59AD-363D-11E5-9242-09173F13E4C5 n9:271B59AE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5A03-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5A05-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5A06-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5A02-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5A01-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5A04-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B59F2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B59FF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5A00-363D-11E5-9242-09173F13E4C5